secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001558370-22-015722
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q3 2022 net revenue $117.2M, up 45% YoY; GAAP EPS $1.44, non-GAAP EPS $0.95
--------------------------------------------------------------------------------

- Net product revenue $117.2M (+45% vs Q3 2021); average WAKIX patients ~4,600.
- GAAP net income $87.9M ($1.44 diluted EPS) vs loss of $9.6M in prior year; includes $74.5M tax benefit.
- Non-GAAP adjusted net income $58.1M ($0.95 diluted EPS) vs $23.4M ($0.41) in prior year.
- PWS Phase 2 POC study positive signal on EDS; high-dose pitolisant higher responder rate vs placebo.
- Cash, cash equivalents & investments $316M as of Sep 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837022015722/0001558370-22-015722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837022015722/hrmy-20221101x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-015722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer